Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2023-11-08

FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for SCEMBLIX (asciminib) submitted by Novartis Pharmaceuticals Corporation. The action involves changes to the product l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SCEMBLIX (ASCIMINIB)

Snippet

SUPPL AP for SCEMBLIX (ASCIMINIB)